Astellas won the FDA’s approval to market Cresemba (isavuconazonium sulfate) in the US as a treatment for two rare but serious infections, invasive aspergillosis and invasive mucormycosis.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?